keyword
MENU ▼
Read by QxMD icon Read
search

DLBCL

keyword
https://www.readbyqxmd.com/read/27919680/aldh1a1-induces-resistance-to-chop-in-diffuse-large-b-cell-lymphoma-through-activation-of-the-jak2-stat3-pathway
#1
Jinqiong Jiang, Yiping Liu, Youhong Tang, Li Li, Ruolan Zeng, Shan Zeng, Meizuo Zhong
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), chemoresistance is a common cause of treatment failure. This study aims to investigate the significance of aldehyde dehydrogenase (ALDH) 1A1 expression and the mechanism by which ALDH1A1 is involved in chemoresistance of DLBCL cells. ALDH1A1 expression levels were upregulated in patients with stable or progressive disease after CHOP treatment and positively correlated with expression of STAT3 and p-STAT3...
December 2, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27915469/myd88-cd79b-and-card11-gene-mutations-in-cd5-positive-diffuse-large-b-cell-lymphoma
#2
Toshifumi Takeuchi, Motoko Yamaguchi, Kyoko Kobayashi, Kana Miyazaki, Isao Tawara, Hiroshi Imai, Ryoichi Ono, Tetsuya Nosaka, Kyosuke Tanaka, Naoyuki Katayama
BACKGROUND: CD5-positive (CD5(+) ) diffuse large B-cell lymphoma (DLBCL) is characterized by frequent central nervous system recurrence and a predominant activated B-cell-like nature. Primary DLBCL in sanctuary sites (DLBCL-SS) also demonstrates these features, and >70% of patients harbor myeloid differentiation primary response 88 (MYD88) (L265P) and CD79B mutations. The objective of the current study was to elucidate a possible relationship between CD5(+) DLBCL and DLBCL-SS. METHODS: MYD88, CD79B, CD79A, and caspase recruitment domain family member 11 (CARD11) mutations were examined in samples from 40 patients with CD5(+) DLBCL...
December 4, 2016: Cancer
https://www.readbyqxmd.com/read/27913781/synchronous-microscopic-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma-of-the-adrenal-and-lymphoplasmacytic-lymphoma-de-novo-disease-or-transformation
#3
Mufaddal T Moonim, Alia Nasir, Jonathan Hubbard, Nicholas Ketley, Paul Fields
Lymphomas arising in the adrenal are rare, and to our knowledge, 2 cases of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (DLBCL) in an adrenal pseudocyst have been reported. We report an incidental EBV-positive DLBCL arising in an adrenal pseudocyst in a 58-year-old man with a 7-year history of lymphoplasmacytic lymphoma (LPL). The DLBCL was present in the fibrinous exudate, while the LPL resided in the cyst wall. The patient underwent de-roofing of the same cyst 3 years previously; review of histology revealed foci of LPL in the cyst wall, but not of DLBCL...
December 2, 2016: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27913505/management-of-primary-central-nervous-system-lymphoma-in-children
#4
Lisa Giulino-Roth, Oussama Abla, Tracy T Batchelor
A 14-year-old boy with no significant past medical history presents with headaches and vomiting and is found to have a 2 × 3-cm left parietal lobe mass. A stereotactic biopsy reveals diffuse large B-cell lymphoma (DLBCL). Cerebrospinal fluid cytology, as well as bone marrow biopsies are negative, and a whole-body positron emission tomography/computed tomography scan does not demonstrate other areas of disease. The primary medical team asks how you would treat this patient.
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27913503/diffuse-large-b-cell-lymphoma-r-chop-failure-what-to-do
#5
Bertrand Coiffier, Clémentine Sarkozy
Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL), ∼30% to 50% of patients are not cured by this treatment, depending on disease stage or prognostic index. Among patients for whom R-CHOP therapy fails, 20% suffer from primary refractory disease (progress during or right after treatment) whereas 30% relapse after achieving complete remission (CR). Currently, there is no good definition enabling us to identify these 2 groups upon diagnosis...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27907212/diffuse-large-b-cell-lymphoma-cell-line-u-2946-model-for-mcl1-inhibitor-testing
#6
Hilmar Quentmeier, Hans G Drexler, Vivien Hauer, Roderick A F MacLeod, Claudia Pommerenke, Cord C Uphoff, Margarete Zaborski, Mattias Berglund, Gunilla Enblad, Rose-Marie Amini
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma worldwide. We describe the establishment and molecular characteristics of the DLBCL cell line U-2946. This cell line was derived from a 52-year-old male with DLBCL. U-2946 cells carried the chromosomal translocation t(8;14) and strongly expressed MYC, but not the mature B-cell lymphoma associated oncogenes BCL2 and BCL6. Instead, U-2946 cells expressed the antiapoptotic BCL2 family member MCL1 which was highly amplified genomically (14n)...
2016: PloS One
https://www.readbyqxmd.com/read/27904766/the-role-of-pim1-in-the-ibrutinib-resistant-abc-subtype-of-diffuse-large-b-cell-lymphoma
#7
Hsu-Ping Kuo, Scott A Ezell, Sidney Hsieh, Karl J Schweighofer, Leo Wk Cheung, Shiquan Wu, Mutiah Apatira, Mint Sirisawad, Karl Eckert, Yu Liang, Jeff Hsu, Chun-Te Chen, Darrin Beaupre, Betty Y Chang
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous lymphoma and the most common subtype of non-Hodgkin lymphoma, accounting for roughly 30% of newly diagnosed cases in the United States. DLBCL can be separated into the activated B cell-like (ABC) and germinal center B cell-like (GCB) subtypes, with distinct gene expression profiles, oncogenic aberrations, and clinical outcomes. ABC-DLBCL is characterized by chronically active B-cell receptor (BCR) signaling that can be modulated by Bruton's tyrosine kinase (BTK) activity...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27901328/prognostic-value-of-interim-fdg-pet-ct-in-patients-older-than-60-years-with-diffuse-large-b-cell-lymphoma-treated-by-pmitcebo-plus-rituximab-comparison-between-deauville-5-point-scale-and-international-harmonization-project-criteria
#8
Naelle Lombion, Philippe Robin, Adrian Tempescul, Pierre Y LE Roux, Ulrike Schick, Gaëlle Guillerm, Jean C Ianotto, Christian Berthou, Pierre Y Salaün, Ronan Abgral
BACKGROUND: Advanced age is an independent poor prognostic factor of diffuse large B-cell lymphoma. PMitCEBO is an alternative to CHOP to decrease side effects in elderly patients. Many studies have shown prognostic value of an interim FDG PET-CT to predict survival. A recent consensus (ICML, Lugano 2013) has suggested using the 5-point scale Deauville criteria instead of those of the international harmonization project (IHP) to visually assess the response on interim PET. The objective of this study was to evaluate the prognostic value of an interim FDG PET-CT in patients older than 60 with treated DLBCL and to compare IHP and 5-PS Deauville visual interpretation to predict survival...
November 30, 2016: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27899414/sentinel-case-of-richter-transformation-from-chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma-to-cd3-diffuse-large-b-cell-lymphoma
#9
Ali Ismail, Jawed A Mallick, Dahui Qin, Mohammad O Hussaini
AIM: To report the first case of a Richter syndrome where small lymphocytic lymphoma (SLL) progressed to a CD3+ diffuse large B-cell lymphoma (DLBCL). METHODS: Macrodissection of small and large cell lymphomatous components was performed. This was followed by flow cytometric analysis along with molecular B-cell immunoglobulin (heavy and light chains) and T-cell receptor (γ and β chains) gene rearrangement studies to investigate a clonal relationship between the components...
November 29, 2016: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27897411/skeletal-muscle-density-is-an-independent-predictor-of-diffuse-large-b-cell-lymphoma-outcomes-treated-with-rituximab-based-chemoimmunotherapy
#10
Michael P Chu, Jessica Lieffers, Sunita Ghosh, Andrew Belch, Neil S Chua, Amelie Fontaine, Randeep Sangha, Robert A Turner, Vickie E Baracos, Michael B Sawyer
BACKGROUND: While much cancer research focuses on tumours and their microenvironment, malignancies cause widespread physiologic changes. Cancer and treatment-related sarcopenia, measured with quantitative imaging or as a decrease in overall body mass, are indicative of poor prognosis in elderly diffuse large B-cell lymphoma (DLBCL) patients, skeletal muscle radiodensity (SMD) may be a better prognostic marker. SMD, a measure of muscle radiation attenuation on CT imaging, is more prognostic than sarcopenia or International Prognostic Index (IPI) scores in follicular lymphoma and multiple solid organ malignancies...
November 21, 2016: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/27893172/anthropometrics-and-prognosis-in-diffuse-large-b-cell-lymphoma-a-multicentre-study-of-653-patients
#11
Mette Dahl Bendtsen, Peter Svenssen Munksgaard, Marianne Tang Severinsen, Eric Bekric, Christian Brieghel, Kristina Buchardi Nielsen, Peter de Nully Brown, Karen Dybkaer, Hans Erik Johnsen, Martin Bøgsted, Tarec Christoffer El-Galaly
OBJECTIVE: The impact of body mass index (BMI) and body surface area (BSA) on survival in diffuse large B-cell lymphoma (DLBCL) is controversial. Recent studies show superior outcomes for overweight and obese patients. PATIENTS AND METHODS: 653 R-CHOP(-like) treated DLBCL patients were included in this retrospective cohort study. Patients, baseline clinicopathologic characteristics and treatment information were retrieved from the Danish Lymphoma Registry. Anthropometric measures were obtained from chemotherapy prescription charts...
November 28, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27888879/gray-zone-lymphoma-current-diagnosis-and-treatment-options
#12
REVIEW
Monika Pilichowska, Athena Kritharis, Andrew M Evens
The morphology of gray zone lymphoma (GZL) is variable with tumor cells spanning the spectrum of diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma. The immunophenotype is frequently discordant. Clinically, the initial case descriptions of GZL were primarily with mediastinal presentation; however, a nonmediastinal (systemic) clinical subtype is now recognized. Patients with GZL have high relapse rates. Recommended treatment of GZL is with a DLBCL-directed regimen with consideration for consolidative radiotherapy for bulk disease...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27888877/promising-novel-agents-for-aggressive-b-cell-lymphoma
#13
REVIEW
Anas Younes
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in the western world. Current treatment regimens result in curing approximately 50% to 60% of patients with DLBCL. In 2006, the Food and Drug Administration approved rituximab for use in the first-line treatment of patients with DLBCL in combination with anthracycline-based chemotherapy regimens. Since then, no other agents have been approved for the treatment of DLBCL. This article reviews recent data on the most promising agents in development for the treatment of DLBCL...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27888875/management-of-relapsed-diffuse-large-b-cell-lymphoma
#14
REVIEW
Michael Crump
Second-line therapy options for patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to, or relapses after, current rituximab-containing primary therapy continue to evolve. For younger patients, salvage therapy followed by intensive therapy and autologous stem cell transplant (ASCT) remains the treatment of choice for those with chemotherapy-sensitive disease. Combination therapy may be used for those who are not candidates for ASCT. In contrast, patients with DLBCL refractory to 2 lines of therapy have a very poor prognosis and generally short survival, and should be carefully considered for participation in clinical trials of novel approaches...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27888873/molecular-classification-of-diffuse-large-b-cell-lymphoma-what-is-clinically-relevant
#15
REVIEW
Pierre Sujobert, Gilles Salles, Emmanuel Bachy
Major progress in the understanding of diffuse large B-cell lymphoma (DLBCL) biology has been made in the last decade. Many specific compounds have now entered early phase clinical trials. However, further efforts are needed to find an accurate, fast, reproducible, and affordable technique to translate DLBCL subtype determination by gene expression profiles into clinical application. This article discusses the advantages and drawbacks of the currently available techniques of DLBCL subtype determination as well as important prognostic implications related to the cell of origin...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27888872/state-of-the-art-therapy-for-advanced-stage-diffuse-large-b-cell-lymphoma
#16
REVIEW
Annalisa Chiappella, Alessia Castellino, Umberto Vitolo
Diffuse large B-cell lymphoma (DLBCL) represents the most common lymphoid malignancy in adults, with a median age of 60 to 70 years. Clinical behavior is usually rapidly aggressive, with extranodal involvement in 40% of cases. Chemoimmunotherapy administered every 21 days is still the standard of care in the advanced stage. Optimization of frontline therapy and the amelioration of salvage strategies remain the most important targets in the treatment of patients with DLBCL. Novel drugs directed to specific molecular targets have been introduced as single agents or in addition to standard chemoimmunotherapy for the treatment of DLBCL...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27888658/a-case-of-composite-classical-and-nodular-lymphocyte-predominant-hodgkin-lymphoma-with-progression-to-diffuse-large-b-cell-non-hodgkin-lymphoma-diagnostic-difficulty-in-fine-needle-aspiration-cytology
#17
Dilip K Das, Zafar A Sheikh, Mariam H Al-Shama'a, Bency John, Abdulla M S Alawi, Thamradeen A Junaid
A small percentage of nodular lymphocytic predominant Hodgkin lymphoma (NLPHL) progresses to diffuse large B-cell lymphoma (DLBCL). There have also been rare reports of gray zone lymphoma with features intermediate between classical Hodgkin lymphoma (CHL) and DLBCL. We report a very rare case of composite lymphoma (CHL and NLPHL) progressing to DLBCL, and highlight the diagnostic difficulty faced during its fine-needle aspiration (FNA) cytology diagnosis. A 65-year-old woman presented with a right axillary swelling which was subjected to FNA cytology...
November 26, 2016: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/27888017/circulating-cxcr5-cd4-t-cells-assist-in-the-survival-and-growth-of-primary-diffuse-large-b-cell-lymphoma-cells-through-interleukin-10-pathway
#18
Zhanshan Cha, Guangfang Qian, Yan Zang, Haihui Gu, Yanyan Huang, Lishuang Zhu, Jinqi Li, Yang Liu, Xiaohua Tu, Haihan Song, Baohua Qian
Diffuse large B cell lymphoma (DLBCL) is a common and aggressive cancer caused by the malignant transformation of B cells. Although it has been established that the follicular helper T (Tfh) cells play a central role in B cell development, little information is available on their involvement in DLBCL pathogenesis. We studied the role of the peripheral Tfh equivalent, the CXCR5(+) CD4(+) T cells, in DLBCL. Data showed that compared to CXCR5(-) CD4(+) T cells, CXCR5(+) CD4(+) T cells were significantly more effective at promoting the proliferation as well as inhibiting the apoptosis of primary autologous DLBCL tumor cells...
November 23, 2016: Experimental Cell Research
https://www.readbyqxmd.com/read/27887763/composite-lymphoma-with-diffuse-large-b-cell-lymphoma-and-classical-hodgkin-lymphoma-components-a-case-report-and-review-of-the-literature
#19
Gaurav Goyal, Austin Huy Nguyen, Kayla Kendric, Gabriel C Caponetti
Composite lymphoma (CL) is an infrequently diagnosed entity in which two or more distinct types of lymphomas occur synchronously in the same organ or anatomical site. Most commonly, CLs are composed of two non-Hodgkin B-cell lymphomas. We present a case of a composite lymphoma with diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS) and classical Hodgkin lymphoma (CHL) components involving the terminal ileum, colon and pericolic lymph nodes. Immunohistochemical evaluation for determination of cell of origin of the DLBCL-NOS component indicated a germinal center B-cell subtype...
December 2016: Pathology, Research and Practice
https://www.readbyqxmd.com/read/27881887/changes-in-sexuality-body-image-and-health-related-quality-of-life-in-patients-treated-for-hematologic-malignancies-a-longitudinal-study
#20
Cecilia Olsson, Ann-Kristin Sandin-Bojö, Kaisa Bjuresäter, Maria Larsson
Longitudinal studies exploring sexuality, body image and health-related quality of life (HRQoL) are lacking in patients treated with chemo- or chemoimmuno-therapy for hematologic malignancies. The aim was to describe and explore changes in sexuality, body image and HRQoL in patients treated for hematologic malignancies, from baseline until 6 months after treatment. Twenty patients above 45 years (median age 62) treated for DLBCL, CLL or AML participated. Data were collected at baseline, 1- and 6-months after treatment by means of three instruments: SAQ-S, BIS and EORTC QLQ-C30...
2016: Sexuality and Disability
keyword
keyword
98
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"